Although momelotinib synergized with a MEK inhibitor and potently induced regression of aggressive K-RAS-p53 mutated murine lung tumors, the combination was ineffective in patients suffering from refractory, metastatic, K-RAS-mutated NSCLC [54,109]. Here, KRAS is linked to non-small cell lung carcinoma.